Kuehn Law says it is investigating Geron officers over Rytelo allegations
Kuehn Law said it is investigating whether certain Geron Corporation officers and directors breached fiduciary duties, citing allegations tied to the launch of Rytelo.
Kuehn Law, PLLC said Tuesday it is investigating whether certain officers and directors of Geron Corporation breached fiduciary duties to shareholders, citing allegations in a federal securities lawsuit tied to the launch and performance of Rytelo.
The notice centers on claims that Geron misrepresented or failed to disclose the state of its only commercial product. The allegations remain unproven, but the firm says they raise questions about what company leaders knew and when they knew it.
In the PR Newswire notice, Kuehn Law said the suit alleges Rytelo’s commercial launch was “plagued by open conflict” between Geron’s medical and commercial teams. The notice also says the sales force was sent into the market without marketing materials beyond the FDA prescribing information, and that Geron failed to educate its primary target market, community physicians, about Rytelo.
The same notice says Rytelo’s growth and revenue flattened only weeks after launch. It identifies Geron as Nasdaq-listed under the ticker GERN.
Rytelo is described in the notice as Geron’s sole commercial product. The firm’s solicitation says it is focused on whether company officers and directors breached duties to shareholders in connection with the product’s rollout and disclosures.
Kuehn Law’s notice was dated Sept. 2, 2026, and said it was published from New York. It also said current GERN holders who purchased before Feb. 28, 2024 should contact Sophia Anne Silayan by email or at (833) 672-0814.
The notice says Kuehn Law pays all case costs and does not charge investor clients. It also warns that shareholders may have limited time to enforce their rights. The item includes an attorney-advertising disclaimer and says prior results do not guarantee similar outcomes.
What happens next is not clear from the notice. The firm is seeking contact from affected investors, and the underlying securities claims referenced in the solicitation are described only as allegations.
Sources
Editorial note: This article was prepared with AI assistance and includes source attribution for reader review.
View the Web StoryA visual, tap-through version of this reportThis is the AMP version of the article. Read the full article on Atlas Watchline.